About: Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial
Creator	Mao, Bing Xu, Yan-Ling Zhang, Rui-Ming Dong, Shou-Jin Chang, Jing Meng, Mao-Bin Pan, Jun-Hun She, Bin Shi, Ke-Hua Wan, Li-Ling
Source	Medline; PMC
abstract	This study was designed to determine the therapeutic efficacy and safety of the Shi-cha capsule, a Chinese herbal formula, in the treatment of patients with wind-cold type common cold. In our multi-center, prospective, double-blind, randomized, placebo-controlled, dose-escalation trial, patients with wind-cold type common cold received 0.6 g of Shi-cha capsule plus 0.6 g placebo (group A), 1.2 g of Shi-cha capsule (group B), or 1.2 g placebo (group C), three times daily for 3 days and followed up to 10 days. The primary end point was all symptom duration. The secondary end points were main symptom duration, minor symptom duration, the changes in cumulative symptom score, main symptom score, and minor symptom score 4 days after the treatment, as well as adverse events. A total of 377 patients were recruited and 360 met the inclusive criteria; 120 patients constituted each treatment group. Compared with patients in group C, patients in groups A and B had significant improvement in the all symptom duration, main symptom duration, minor symptom duration, as well as change from baseline of cumulative symptom score, main symptom score, and minor symptom score at day 4. The symptom durations and scores showed slight superiority of group B over group A, although these differences were not statistically significant. There were no differences in adverse events. The Shi-cha capsule is efficacious and safe for the treatment of patients with wind-cold type common cold. Larger trials are required to fully assess the benefits and safety of this treatment for common cold.
has issue date	2012-12-27(xsd:dateTime)
bibo:doi	10.1155/2012/254571
bibo:pmid	23346193
has license	cc-by
sha1sum (hex)	ec64f7f7ece2c16fb0a4210295b2527714b11ee0
schema:url	https://doi.org/10.1155/2012/254571
resource representing a document's title	Treatment of Common Cold Patients with the Shi-Cha Capsule: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial
has PubMed Central identifier	PMC3544370
has PubMed identifier	23346193
schema:publication	Evid Based Complement Alternat Med
resource representing a document's body	covid:ec64f7f7ece2c16fb0a4210295b2527714b11ee0#body_text
is schema:about of	named entity 'patients' named entity 'group C' named entity 'group A' named entity 'symptom' named entity 'double-blind' named entity 'group A' named entity 'Patients' named entity 'Randomized' named entity 'DURATION' named entity 'COMMON COLD' named entity 'RANDOMIZED' covid:arg/ec64f7f7ece2c16fb0a4210295b2527714b11ee0 named entity 'THREE TIMES DAILY' named entity 'GROUPS' named entity 'FORMULA' named entity 'DAYS' named entity 'OUR' named entity 'CRITERIA' named entity 'RECEIVED' named entity 'SAFE' named entity 'COMMON COLD' named entity 'FULLY' named entity 'CHINESE' named entity '0.6' named entity 'DOSE-ESCALATION' named entity 'STUDY' named entity 'REQUIRED' named entity '120' named entity 'BLIND' named entity 'MET' named entity 'SLIGHT' named entity 'INCLUSIVE' named entity 'HERBAL' named entity 'DETERMINE' named entity 'SUPERIORITY' named entity 'DOUBLE' named entity 'PLACEBO-CONTROLLED' named entity 'PATIENTS' named entity 'CHA' named entity 'CAPSULE' named entity 'TREATMENT' named entity 'SHI' named entity 'SCORE 4' named entity 'DOUBLE' named entity 'SAFETY' named entity 'SCORES' named entity 'POINTS' named entity 'UP TO' named entity 'COMPARED' named entity 'SYMPTOM SCORE' named entity 'SECONDARY' named entity 'SHI' named entity 'END' named entity 'MINOR' named entity 'MULTI' named entity 'CHANGE FROM BASELINE' named entity 'BLIND' named entity 'GROUP C' named entity 'DURATIONS' named entity 'CHANGES' named entity '1.2' named entity 'STATISTICALLY SIGNIFICANT' named entity 'GROUP A' named entity 'TREATMENT' named entity 'DAY 4' named entity 'ADVERSE EVENTS' named entity 'BENEFITS' named entity 'THESE' named entity 'PATIENTS' named entity 'TYPE' named entity 'LARGER' named entity 'CHA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software